Diagnostic and prognostic value of independent and combined detection of computed tomography, ultrasound, and positron emission tomography - computed tomography in lymphoma

被引:1
作者
Shi, Lihong [1 ]
Hu, Haihua [2 ]
机构
[1] Huzhou Cent Hosp, Dept Ultrasound Med, Huzhou 313000, Peoples R China
[2] Huzhou Zhebei Mingzhou Hosp, Dept Nucl Med, Huzhou 313000, Peoples R China
来源
SLAS TECHNOLOGY | 2024年 / 29卷 / 04期
关键词
PET-CT; Ultrasound; Lymphoma; Anti-tumor; Prognosis value; INTERNATIONAL EXTRANODAL LYMPHOMA; STAGE HODGKIN LYMPHOMA; RADIOTHERAPY; PET/CT; CHEMOIMMUNOTHERAPY; RANDOMIZATION; METHOTREXATE; MULTICENTER; RITUXIMAB; PHASE-3;
D O I
10.1016/j.slast.2024.100165
中图分类号
Q5 [生物化学];
学科分类号
071010 ; 081704 ;
摘要
Lymphoma is a malignant tumor originating from the lymphopoietic system, which can affect all tissues and organs of the body. Lymphoma is highly heterogeneous and the therapeutic effect varies greatly. Different pathological types and stages of lymphoma differ greatly in terms of treatment intensity and prognosis. Early diagnosis of lymphoma is very important to improve the prognosis of patients. Therefore, this work explored the diagnostic value of independent and combined detection of computed tomography (CT), ultrasound, and positron emission tomography - computed tomography (PET-CT) for lymphoma. The sensitivity, specificity, positive predictive value (PPV), and negative predictive value (NPV) in the PET-CT and combination groups were greatly higher than those in the CT and ultrasound groups, showing obvious differences (P < 0.05). The area under curve (AUC) values in the CT group, ultrasound group, PET-CT group, and combination group were 0.632 (P = 0.032), 0.614 (P = 0.025), 0.793 (P = 0.002), and 0.859 (P = 0.001), respectively, exhibiting observable differences (P < 0.05). the sensitivity and specificity of PET/CT for lymphoma were higher than those of CT and ultrasound, which can clearly show the early mild results of lymphatic lymphoma. Therefore, the combined diagnosis of lymphatic lymphoma with PET/CT was of high clinical value.
引用
收藏
页数:6
相关论文
共 27 条
  • [1] Romidepsin Plus CHOP Versus CHOP in Patients With Previously Untreated Peripheral T-Cell Lymphoma: Results of the Ro-CHOP Phase III Study (Conducted by LYSA)
    Bachy, Emmanuel
    Camus, Vincent
    Thieblemont, Catherine
    Sibon, David
    Casasnovas, Rene-Olivier
    Ysebaert, Loic
    Damaj, Gandhi
    Guidez, Stephanie
    Pica, Gian Matteo
    Kim, Won Seog
    Lim, Soon Thye
    Andre, Marc
    Garcia-Sancho, Alejandro Martin
    Penarrubia, Maria Jesus
    Staber, Philipp B.
    Trotman, Judith
    Huettmann, Andreas
    Stefoni, Vittorio
    Re, Alessandro
    Gaulard, Philippe
    Delfau-Larue, Marie-Helene
    de Leval, Laurence
    Meignan, Michel
    Li, Ju
    Morschhauser, Franck
    Delarue, Richard
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (03) : 242 - +
  • [2] Sustained Progression-Free Survival Benefit of Rituximab Maintenance in Patients With Follicular Lymphoma: Long-Term Results of the PRIMA Study
    Bachy, Emmanuel
    Seymour, John F.
    Feugier, Pierre
    Offner, Fritz
    Lopez-Guillermo, Armando
    Belada, David
    Xerri, Luc
    Catalano, John V.
    Brice, Pauline
    Lemonnier, Francois
    Martin, Alejandro
    Casasnovas, Olivier
    Pedersen, Lars M.
    Dorvaux, Veronique
    Simpson, David
    Leppa, Sirpa
    Gabarre, Jean
    da Silva, Maria G.
    Glaisner, Sylvie
    Ysebaert, Loic
    Vekhoff, Anne
    Intragumtornchai, Tanin
    Le Gouill, Steven
    Lister, Andrew
    Estell, Jane A.
    Milone, Gustavo
    Sonet, Anne
    Farhi, Jonathan
    Zeuner, Harald
    Tilly, Herve
    Salles, Gilles
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (31) : 2815 - +
  • [3] Borchmann P, 2021, LANCET ONCOL, V22, P223, DOI 10.1016/S1470-2045(20)30601-X
  • [4] Long-term efficacy and safety of CT-P10 or rituximab in untreated advanced follicular lymphoma: a randomized phase 3 study
    Buske, Christian
    Jurczak, Wojciech
    Sancho, Juan-Manuel
    Zhavrid, Edvard
    Kim, Jin Seok
    Hernandez-Rivas, Jose-Angel
    Prokharau, Aliaksandr
    Vasilica, Mariana
    Nagarkar, Rajnish
    Kwak, Larry
    Kim, Won-Seog
    Lee, SangJoon
    Kim, SungHyun
    Ahn, KeumYoung
    Ogura, Michinori
    [J]. BLOOD ADVANCES, 2021, 5 (17) : 3354 - 3361
  • [5] Recommendations for Initial Evaluation, Staging, and Response Assessment of Hodgkin and Non-Hodgkin Lymphoma: The Lugano Classification
    Cheson, Bruce D.
    Fisher, Richard I.
    Barrington, Sally F.
    Cavalli, Franco
    Schwartz, Lawrence H.
    Zucca, Emanuele
    Lister, T. Andrew
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (27) : 3059 - +
  • [6] Prognostic value of baseline metabolic tumor volume in early-stage Hodgkin lymphoma in the standard arm of the H10 trial
    Cottereau, Anne-Segolene
    Versari, Annibale
    Loft, Annika
    Casasnovas, Olivier
    Bellei, Monica
    Ricci, Romain
    Bardet, Stephane
    Castagnoli, Antonio
    Brice, Pauline
    Raemaekers, John
    Deau, Benedicte
    Fortpied, Catherine
    Raveloarivahy, Tiana
    Van Zele, Emelie
    Chartier, Loic
    Borght, Thierry Vander
    Federico, Massimo
    Hutchings, Martin
    Ricardi, Umberto
    Andre, Marc
    Meignan, Michel
    [J]. BLOOD, 2018, 131 (13) : 1456 - 1463
  • [7] Whole-brain radiotherapy or autologous stem-cell transplantation as consolidation strategies after high-dose methotrexate-based chemoimmunotherapy in patients with primary CNS lymphoma: results of the second randomisation of the International Extranodal Lymphoma Study Group-32 phase 2 trial
    Ferreri, Andres J. M.
    Cwynarski, Kate
    Pulczynski, Elisa
    Fox, Christopher P.
    Schorb, Elisabeth
    La Rosee, Paul
    Binder, Mascha
    Fabbri, Alberto
    Torri, Valter
    Minacapelli, Eleonora
    Falautano, Monica
    Ilariucci, Fiorella
    Ambrosetti, Achille
    Roth, Alexander
    Hemmaway, Claire
    Johnson, Peter
    Linton, Kim M.
    Pukrop, Tobias
    Gorlov, Jette Sonderskov
    Balzarotti, Monica
    Hess, Georg
    Keller, Ulrich
    Stilgenbauer, Stephan
    Panse, Jens
    Tucci, Alessandra
    Orsucci, Lorella
    Pisani, Francesco
    Levis, Alessandro
    Krause, Stefan W.
    Schmoll, Hans J.
    Hertenstein, Bernd
    Rummel, Mathias
    Smith, Jeffery
    Pfreundschuh, Michael
    Cabras, Giuseppina
    Angrilli, Francesco
    Ponzoni, Maurilio
    Deckert, Martina
    Politi, Letterio S.
    Finke, Juergen
    Reni, Michele
    Cavalli, Franco
    Zucca, Emanuele
    Illerhaus, Gerald
    [J]. LANCET HAEMATOLOGY, 2017, 4 (11): : E510 - E523
  • [8] Chemoimmunotherapy with methotrexate, cytarabine, thiotepa, and rituximab (MATRix regimen) in patients with primary CNS lymphoma: results of the first randomisation of the International Extranodal Lymphoma Study Group-32 (IELSG32) phase 2 trial
    Ferreri, Andres J. M.
    Cwynarski, Kate
    Pulczynski, Elko
    Ponzoni, Mourilio
    Deckert, Martina
    Politi, Letterio S.
    Torri, Valter
    Fox, Christopher P.
    La Rosee, Paul
    Schorb, Elisabeth
    Ambrosetti, Achille
    Roth, Alexander
    Hemmoway, Claire
    Ferrari, Angela
    Linton, Kim M.
    Ruda, Roberta
    Binder, Mascha
    Pukrop, Tobias
    Balzarotti, Monica
    Fabbri, Alberto
    Johnson, Peter
    Gorlov, Jette Sonderskov
    Hess, Georg
    Panse, Jens
    Pisani, Francesco
    Tucci, Alessandra
    Stilgenbauer, Stephan
    Hertenstein, Bernd
    Keller, Ulrich
    Krause, Stefan W.
    Levis, Alessandro
    Schmoll, Hans J.
    Covalli, Franco
    Finke, Jurgen
    Reni, Michele
    Zucca, Emanuele
    Illerhaus, Gerald
    [J]. LANCET HAEMATOLOGY, 2016, 3 (05): : E217 - E227
  • [9] Analysis of self-reported activities of daily living, motor performance and physical activity among children and adolescents with cancer: Baseline data from a randomised controlled trial assessed shortly after diagnosis of leukaemia or non-Hodgkin lymphoma
    Gaser, Dominik
    Peters, Christiane
    Goette, Miriam
    Oberhoffer-Fritz, Renate
    Feuchtinger, Tobias
    Schmid, Irene
    von Luettichau, Irene
    Kesting, Sabine
    [J]. EUROPEAN JOURNAL OF CANCER CARE, 2022, 31 (02)
  • [10] 4 Gy versus 24 Gy radiotherapy for follicular and marginal zone lymphoma (FoRT): long-term follow-up of a multicentre, randomised, phase 3, non-inferiority trial
    Hoskin, Peter
    Popova, Biliana
    Schofield, Oliver
    Brammer, Caroline
    Robinson, Martin
    Brunt, A. Murray
    Madhavan, Krishnaswamy
    Illidge, Tim
    Gallop-Evans, Eve
    Syndikus, Isabel
    Clifton-Hadley, Laura
    Kirkwood, Amy A.
    [J]. LANCET ONCOLOGY, 2021, 22 (03) : 332 - 340